Patents by Inventor Venkata P. Palle

Venkata P. Palle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210052556
    Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.
    Type: Application
    Filed: March 26, 2020
    Publication date: February 25, 2021
    Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20200101068
    Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.
    Type: Application
    Filed: August 13, 2016
    Publication date: April 2, 2020
    Applicant: Lupin Limited
    Inventors: Navnath Popat Karche, Ajay Ramchandra Tilekar, Sanjay Pralhad Kurhade, Ganesh Rajaram Jadhav, Nishant Ramniwasji Gupta, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20190275012
    Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.
    Type: Application
    Filed: July 28, 2017
    Publication date: September 12, 2019
    Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20190160045
    Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.
    Type: Application
    Filed: July 28, 2017
    Publication date: May 30, 2019
    Inventors: Gagan Kukreja, Nageswara Rao Irlapati, Arun Rangnath Jagdale, Gokul Keruji Deshmukh, Vinod Popatrao Vyavahare, Kiran Chandrashekhar Kulkarni, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 10292981
    Abstract: The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: May 21, 2019
    Assignee: LUPIN LIMITED
    Inventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 10239869
    Abstract: The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.
    Type: Grant
    Filed: September 3, 2016
    Date of Patent: March 26, 2019
    Assignee: LUPIN LIMITED
    Inventors: Vidya Ramdas, Rajeshkumar Maganlal Loriya, Moloy Banerjee, Pradeep Rangrao Patil, Advait Arun Joshi, Laxmikant Shamlal Datrange, Deepak Sahebrao Walke, Talha Hussain Khan, Amit Kumar Das, Ganesh Navinchandra Gote, Vaibhav Madhukar Kalhapure, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20180186777
    Abstract: The present invention relates to sulfonamide compounds Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.
    Type: Application
    Filed: September 3, 2016
    Publication date: July 5, 2018
    Inventors: Vidya RAMDAS, Rajeshkumar Maganlal LORIYA, Moloy BANERJEE, Pradeep Rangrao PATIL, Advait Arun JOSHI, Laxmikant Shamlal DATRANGE, Deepak Sahebrao WALKE, Talha Hussain KHAN, Amit Kumar DAS, Ganesh Navinchandra GOTE, Vaibhav Madhukar KALHAPURE, Venkata P. PALLE, Rajender Kumar KAMBOJ
  • Patent number: 9987249
    Abstract: The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 5, 2018
    Assignee: LUPIN LIMITED
    Inventors: Manojkumar Ramprasad Shukla, Ankush Gangaram Sarde, Rajeshkumar Maganlal Loriya, Vipul Dilip Pachpute, Navnath Bajirao Walke, Talha Hussain Khan, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 9969731
    Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: May 15, 2018
    Assignee: Lupin Limited
    Inventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 9944639
    Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: April 17, 2018
    Assignee: Lupin Limited
    Inventors: Manojkumar Ramprasad Shukla, Nirmal Kumar Jana, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Dipak Raychand Lagad, Anand Jagannath Tarage, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 9827247
    Abstract: The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 28, 2017
    Assignee: Lupin Limited
    Inventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20170304299
    Abstract: The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).
    Type: Application
    Filed: July 6, 2017
    Publication date: October 26, 2017
    Inventors: Nageswara Rao IRLAPATI, Gokul Keruji DESHMUKH, Vijay Pandurang KARCHE, Santosh Madhukar JACHAK, Neelima SINHA, Venkata P. PALLE, Rajender Kumar KAMBOJ
  • Patent number: 9790231
    Abstract: The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: October 17, 2017
    Assignee: LUPIN LIMITED
    Inventors: Nageswara Rao Irlapati, Kiran Chandrashekhar Kulkarni, Vijay Pandurang Karche, Gokul Keruji Deshmukh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 9737534
    Abstract: The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: August 22, 2017
    Assignee: LUPIN LIMITED
    Inventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Patent number: 9725463
    Abstract: The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N; Y is CR3 or N; L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb—; Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 8, 2017
    Assignee: LUPIN LIMITED
    Inventors: Nageswara Rao Irlapati, Nilesh Raghunath Khedkar, Ravindra Babanrao Jape, Rahul Shripad Nandurdikar, Zubair Abdul Wajid Shaikh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20170209410
    Abstract: The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.
    Type: Application
    Filed: January 26, 2017
    Publication date: July 27, 2017
    Inventors: Manojkumar Ramprasad SHUKLA, Ankush Gangaram SARDE, Rajeshkumar Maganlal LORIYA, Vipul Dilip PACHPUTE, Navnath Bajirao WALKE, Talha Hussain KHAN, Sanjeev Anant KULKARNI, Venkata P. PALLE, Rajender Kumar KAMBOJ
  • Publication number: 20170137421
    Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.
    Type: Application
    Filed: July 1, 2015
    Publication date: May 18, 2017
    Applicant: Lupin Limited
    Inventors: Manojkumar Ramprasad Shukla, Nirmal Kumar Jana, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Dipak Raychand Lagad, Anand Jagannath Tarage, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
  • Publication number: 20170137371
    Abstract: The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Inventors: Manojkumar Ramprasad Shukla, Vinod Dinkar Chaudhari, Ankush Gangaram Sarde, Ramesh Dattatraya Phadtare, Mahadeo Bhaskar Tryambake, Dronamraju Prameela, Sanjeev Anant Kulkarni, Rajender Kumar Kamboj, Venkata P. Palle
  • Publication number: 20170137415
    Abstract: The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.
    Type: Application
    Filed: March 27, 2015
    Publication date: May 18, 2017
    Inventors: Vidya RAMDAS, Rajeshkumar Maganlal LORIYA, Deepak Sahebrao WALKE, Amit Kumar DAS, Talha Hussain KHAN, Moloy BANERJEE, Venkata P. PALLE, Rajender Kumar KAMBOJ
  • Patent number: RE47351
    Abstract: N-pyrazole substituted 2-adenosine compounds and methods for using the compounds as A2A-adenosine receptor agonists useful to stimulate mammalian coronary vasodilation for therapeutic purposes and as adjuncts in cardiological imaging.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: April 16, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff A. Zablocki, Elfatih O. Elzein, Venkata P. Palle, Luiz Belardinelli